NEW YORK, NY, December 15, 2023 - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company’s lead drug candidate for amyotrophic lateral sclerosis (ALS). The company’s share price rose nearly 30% in trading on Thursday. https://prismmarketview.com/companies/neurosense-therapeutics-ltd/ Alon Ben-Noon, NeuroSense’s CEO, commented, “As we analyze the PARADIGM trial results, we continue to gain a better...